Schwab Andrew J.
Schwab Andrew J., DIR, reported an open-market or private sale at Skye Bioscience, Inc. involving 409.000000 shares for an estimated $143.15. Reported holdings after the transaction were 55254.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 19, 2026
- Filing date
- Aug 20, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 55,663 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
SKYE price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001598549-26-000005 Common Stock
- Transaction date
- Aug 19, 2026 Filed Aug 20, 2026, 09:59 PM · 1d delay
- Shares
- 409 sh $0.35 per share
- Estimated value
- -$143 Computed from shares × price
- Holdings after
- 55,254 sh Indirect · By 5AM Co-Investors II, L.P.
Filing signal explanations
Badges describe filing facts only — not predictions.
+4 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide…
- F2
The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of…
- (3 footnotes)
power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- F3
The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II…
- F4
The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing memb…
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide…
0 other transactions
0 recent txs